BioLineRx Enters into Share Purchase Agreement with Lincoln Park Capital
During the 36-month term of the purchase agreement, BioLineRx controls
the timing and amount of any sales to LPC, if and when the Company
decides, in accordance with the purchase agreement. LPC has no right to
require the Company to sell any ADSs to LPC, but LPC is obligated to
make purchases as BioLineRx directs, subject to certain conditions. Such
conditions include the effectiveness of a registration statement to be
filed with the
A more detailed description of the purchase agreement is set forth in
the Company’s registration statement on Form F-3 filed today with the
BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company
dedicated to identifying, in-licensing and developing promising
therapeutic candidates. The Company in-licenses novel compounds
primarily from academic institutions and biotech companies based in
BioLineRx’s current portfolio consists of a variety of clinical and
pre-clinical projects, including: BL-1040 for prevention of pathological
cardiac remodeling following a myocardial infarction, which has been
out-licensed to Bellerophon BCM (f/k/a
For more information on BioLineRx, please visit www.biolinerx.com
or download the investor relations mobile device app, which allows users
access to the Company’s ‘SEC documents, press releases, and events.
BioLineRx’s’ IR app is available on the iTunes
LPC is an institutional investor headquartered in
This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor will there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale are unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
Various statements in this release concerning BioLineRx’s future
expectations constitute “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995. These
statements include words such as “may,” “expects,” “anticipates,”
“believes,” and “intends,” and describe opinions about future events.
These forward-looking statements involve known and unknown risks and
uncertainties that may cause the actual results, performance or
achievements of BioLineRx to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Some of these risks are: changes in
relationships with collaborators; the impact of competitive products and
technological changes; risks relating to the development of new
products; and the ability to implement technological improvements. These
and other factors are more fully discussed in the “Risk Factors” section
of BioLineRx’s most recent annual report on Form 20-F filed with the
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D.